DAFTAR PUSTAKA

1. Perhimpunan Dokter Paru Indonesia. Pedoman Diagnosis & Penatalaksanaan Pneumonia Komunitas di Indonesia. Jakarta: Perhimpunan Dokter Paru Indonesia; 2014. h. 1-28.
2. Dahlan Z. Pneumonia. Dalam: Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setyohadi B, Syam AF, editors. Buku Ajar Ilmu Penyakit Dalam. Edisi ke-6. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam FKUI; 2014. h. 1608-12.
3. WHO (2018). The Top 10 Causes of Death. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. –Diakses November 2020
4. Riskesdas (2018). Badan Penelitian dan Pengembangan Kesehatan RI tahun 2018. Riset Kesehatan Dasar. http://www.depkes.go.id/resources/download/infoterkini/materi_rakorpop_2018/Hasil%20Riskesdas%202018.pdf. –Diakses November 2020
5. Mehta MJ, Rekeneire ND, Allore H, Chen S, O'Leary JR, Bauer DC, et al. Modifiable Risk Factors for Pneumonia Requiring Hospitalization among Community-Dwelling Older Adults: The Health, Aging, and Body Composition Study. J Am Geriatr Soc. 2013; 61(7):1111–8.
6. Rumende CM, Rosa Y. Pola Sensitivitas Kuman Penyebab Ventilator-Associated Pneumonia di ICU/HCU RSCM. J Indon Med Assoc. 2016; 66(12):551-7.
7. Alfarizi ME. Pola Mikroorganisme Penyebab Pneumonia dan Sensitivitasnya terhadap Antibiotik di Masyarakat Bandar Lampung (Skripsi). Bandar Lampung: Fakultas Kedokteran, Universitas Lampung; 2017.
8. Hadijah S. Pola Kuman Dan Sensitivitasnya Terhadap Antibiotik Pada Kasus Pneumonia Komunitas Yang Dirawat Di Rsup Dr. M. Djamil Padang Tahun 2016 (Skripsi). Padang: Fakultas Kedokteran, Universitas Andalas; 2018.
9. Cilloniz C, Loeches IM, Vidal CG, Jose AS, Torres A. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns. Int J Mol Sci. 2016; 17(12):1-18.
10. Sinanjung K, Aman AT, Nirwati H. Extended spectrum beta lactamase (ESBL)-producing Klebsiella pneumoniae clinical isolates and its susceptibility pattern to antibiotics at Dr. Soeradji Tirtonegoro General Hospital Klaten, Central Java. J Med Sci. 2020; 52(1):17-27.
11. Khasanah RN, Puspitasari I, Nuryastuti T, Yuniarti N. Prevalensi Multidrug-Resistant Klebsiella pneumonia dan Evaluasi Kesesuaian Antibiotik Empiris Berdasarkan Nilai Prediksi Farmakokinetik Terhadap Outcome Klinis di RSUP Dr. Soeradji Tirtonegoro Klaten. MF. 2020; 16(1):27-33.
12. WHO (2014). Antimicrobial Resistance: Global Report on Surveillance. World Health Organization. https://www.who.int/drugresistance/documents/surveillancereport/en/. –Diakses November 2020.
13. Apriliani NPU, Pinatih KJP. Prevalensi Kelompok Gen blaCTX-M-1 pada Klebsiella pneumoniae di Rumah Sakit Umum Pusat Sanglah Denpasar. E-Jurnal Medika. 2017; 6(2):1-7

14. Parveen RM, Khan MA, Menezes GA, Harish BN, Parija SC, Hays JP. Extended-spectrum β-lactamase producing Klebsiella pneumoniae from blood cultures in Puducherry, India. Indian J Med Res. 2011; 134(3):392–5.
15. Hayati F, Mudatsir, Safariyanti. Uji Aktivitas Antibakteri Ekstrak Etanol Rimpang Kencur (Kaempferia galanga L) Terhada Isolat Klinis Klebsiella penumoniae Secara Invitro. JIM. 2017; 2(1):68-73.
16. Mayasari AP. Klebsiella Pneumoniae Identification Of Producing Extended Spectrum Beta Lactamase (Esbl) And Resistance Pattern Of Antibiotics In Ulin General Hospital Banjarmasin. Berkala Kedokteran. 2017; 13(2):161-5.
17. Zhang J, Zhou K, Zheng B, Zhao L, Shen P, Ji J, et al. High Prevalence of ESBL-Producing Klebsiella pneumoniae Causing Community-Onset Infections in China. Front Microbiol. 2016; 1830(7);1-10.
18. Taslim E, Maskoen TT. Pola Kuman Terbanyak Sebagai Agen Penyebab Infeksi di Intensive Care Unit pada Beberapa Rumah Sakit di Indonesia. JACCOA. 2016; 34(1):56-62.
19. Muztika SA, Nasrul E, Alia E. Prevalensi dan Pola Sensitivitas Antibiotik Klebsiella pneumoniae dan Escherichia coli Penghasil Extended Spectrum Beta Laktamase di RSUP Dr. M. Djamil Padang. JKA. 2020; 9(2):189-94.
20. Paterson DL, Bonomo RA. Extended-Spectrum β-Lactamase: A Clinical Update. Clin Microbiol Rev. 2015; 18(4):657-86.
21. Lestari DC, Karuniawati A, Saharman YR, Sedono R. Patients Infected by Extended-Spectrum Beta-Lactamase Producing Klebsiella pneumoniae: Risk Factors and Outcomes. eJKI. 2020; 8(1):46-51.
22. Deshpande, Jayant D, Joshi, Mohini. Antimicrobial Resistance: The Global Public Health Challenge. IJSR. 2011; 1(2): 1-4.
23. Utami ER. Antibiotika, Resistensi Dan Rasionalitas Terapi. El-Hayah. 2011; 1(4): 191-8.
24. WHO (2019). Pneumonia. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/pneumonia. –Diakses November 2020.
25. Farida Y, Putri VW , Hanafi M, Herdianti NS. Profil Pasien dan Penggunaan Antibiotik pada Kasus Community-Acquired Pneumonia Rawat Inap di Rumah Sakit Akademik Wilayah Sukoharjo. J Pharm Sci Clin Res. 2020; 02:151-164.
26. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015; 373(5):415-27.
27. Patterson CM, Loebinger MR. Community acquired pneumonia: assessment and treatment. Clin Med (Lond). 2012; 12(3):283-6.
28. Rammaert B, Goyet S, Beaute J, Hem S, Te V, Try PL, et al. Klebsiella pneumoniae related community acquired acute lower respiratory infections in Cambodia: Clinical characteristics and treatment. BMC Infect Dis. 2012; 12:1-7.
29. BMJ (2020). Hospital-Acquired Pneumonia. British Medical Journal Best Practice. https://bestpractice.bmj.com/topics/en-us/720. –Diakses November 2020.

30. Feng DY, Zhou YQ, Zou XL, Zhou M, Zhu JX, Wang YH, et al. Differences in microbial etiology between hospital-acquired pneumonia and ventilator-associated pneumonia: a single-center retrospective study in Guang Zhou. Infect Drug Resist. 2019; 12:993-1000.
31. Liu B, Li SQ, Zhang SM, Xu P, Zhang X, Zhang YH, et al. Risk factors of ventilator-associated pneumonia in pediatric intensive care unit: a systematic review and meta-analysis. J Thorac Dis. 2013; 5(4):525-31.
32. Charles MP, Kali A, Easow JM, et al. Ventilator-associated pneumonia. Australas Med J. 2014; 7(8):334-44.
33. ALU (2020). Pneumonia. American Lung Asocciation https://www.lung.org/lung-health-diseases/lung-disease-lookup/pneumonia. –Diakses November 2020.
34. Hage CA, Knox KS, Wheat LJ. Endemic mycoses: overlooked causes of community acquired pneumonia. Respir Med. 2012; 106(6):769-76.
35. Loscalzo J. Harrison's pulmonary and critical care medicine. 2nd ed. New York: The McGraw-Hill Companies, Inc; 2013. p.2013-20.
36. Ekren PK, Toreyin ZN, Takir HB, Balci MK, Gaygisiz U, Gursel G, et al. Evaluation of nephrotoxicity and prognosis in patients treated with colistin due to hospital-acquired pneumonia. Tuber ve Toraks. 2017; 65(4):271-81.
37. Correa RA, Costa AN, Lundgren F, Michelin L, Figueiredo MR, Holanda M, et al. 2018 recommendations for the management of community acquired pneumonia. J Bras Pneumol. 2018; 44(5):405–23.
38. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis. 2007; 44(2):S27–72.
39. Bengoechea JA, Pessoa JS. Klebsiella pneumoniae infection biology: living to counteract host defences. FEMS Microbiol Rev. 2019; 43(2):123-44.
40. Paczosa MK, Mecsas J. Klebsiella pneumoniae: Going on the Offense with a Strong Defense. Microbiol Mol Biol Rev. 2016; 80(3):629–61.
41. MIP (2015). Microbiology In Pictures Gram Negative Bacteria. https://www.microbiologyinpictures.com/klebsiella%20pneumoniae.html. –Diakses November 2020.
42. Brooks GF, Carrol KC, Butel JS, Morse SA, Mietzner TA. Jawetz, Melnick & Adelberg's Medical Microbiology. 26th ed. The McGraw-Hill; 2013. p. 229-36.
43. Brolund A. Overview of ESBL-producing Enterobacteriaceae from a Nordic perspective. Infect Ecol Epidemiol. 2014; 4:245-55.
44. Bush K, Jacoby GA. Updated Functional Classification of Beta Lactamases. AAC. 2010; 54(3):969-76.
45. Rao, Sridhar. Extended Spectrum Beta-Lactamases: A Comprehensive Review. Microrao. 2015:1-108.
46. Biutifasari V. Extended Spectrum Beta-Lactamase (ESBL). OBJ. 2018;1(1):1-11.

47. Anggraini D , Hasanah U, Savira M, Andrini F, Irawan D, Prima R. Prevalensi dan Pola Sensitivitas Enterobacteriaceae Penghasil ESBL di RSUD Arifin Achmad Pekanbaru. JKB. 2018; 30(1):47-52.
48. Tumbarello M, Trecaarichi EM, Basetti M, De Rosa FG, Spanu T, Di Meco E, et al. Identifying patients harboring extended-spectrum-β-lactamaseproducing enterobactericeae on hospital admission: derivation and validation of a scoring system. AAC. 2011; 55(7):3485-90.
49. Wayne, PA. Clinical and Laboratory Standards Institute (CLSI) 2017 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Sevent Informational Supplement. CLSI. 2017; 37(1):M100-S27.
50. Shaikh J, Fatima J, Shakil S, Rizvi S, Kamal M. and Antibiotic Resistance and Extended Spectrum BetaLactamase: Types, Epidemiology, and Treatment. Saudi J Biol Sci. 2015; 22(1):90-101.
51. Musikatavorn K. , Chumpengpan C. , Sujinpram C. Risk Factors of Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae Bacteremia in Thai Emergency Department : a retrospective case-control study. Asian Biomed. 2011; 5(1):129-38.
52. Demirdag, K. , Hosoglu, S. Epidemiology and Risk Factors for ESBLProducing Klebsiella pneumoniae : a Case Control Study. J Infect Dev Ctries. 2010; 4(11):717-22.
53. Lee DS, Lee CB, Lee SJ. Prevalence and risk factors for extended spectrum Beta-lactamase-producing uropathogens in patients with urinary tract infection. Korean J Urol. 2010; 51(7):492-97.
54. Schoevaerdts D, Bogaerts P, Grimmelprez A, de Saint-Hubert M, Delaere B, Jamart J, et al. Clinical profiles of patients colonized or infected with extended-spectrum beta-lactamase producing Enterobacteriaceae isolates: a 20 month retrospective study at a Belgian University Hospital. BMC Infect Dis. 2011; 11(12):1-10.
55. Martin RM, Bachman MA. Colonization, Infection, and the Accessory Genome of Klebsiella pneumoniae. Front Cell Infect Microbiol. 2018; 8(4):1-15.
56. Nham E, Huh K, Cho SY, Chung DR, Peck KR, Lee NY, et al. Characteristics and Clinical Outcomes of Extended-Spectrum beta-lactamase-producing *Klebsiella pneumoniae* Bacteremia in Cancer Patients. Infect Chemother. 2020; 52(1):59-69.
57. Marchaim D, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, et al. National Multicenter Study of Predictors and Outcomes of Bacteremia upon Hospital Admission Caused by Enterobacteriaceae Producing Extended-Spectrum β-Lactamases. AAC. 2010; 54(12):5099-104.
58. Heras IP, Gomez JCS, Martin PB, Pablo LR, Pinedo BL. Community-onset extended-spectrum β-lactamase producing Escherichia coli in urinary tract infections in children from 2015 to 2016: Prevalence, risk factors, and resistances. Medicine. 2017; 96(50):1-3.
59. Koksal E, Tulek N, Sonmezer MC, Temocin F, Bulut C, Hatipoglu C, et al. Investigation of risk factors for community-acquired urinary tract infections

caused by extended-spectrum beta-lactamase Escherichia coli and Klebsiella species. Investig Clin Urol. 2019; 60(1):46-53.
60. Tuon FF, Kruger M, Terreri M, Filho SRP, Gortz L. Klebsiella ESBL bacteremia-mortality and risk factors. Braz J Infect Dis. 2011; 15(6):594-98.
61. Chopra T, Marchaim D, Johnson PC, Chalana IK, Tamam Z, Mohammed M, et al. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime. Am J Infect Control. 2015; 43(7):719-23.
62. Nakai H, Hagihara M, Kato H, Hirai J, Nishiyama N, Koizumi Y, et al. Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. J Infect Chemother. 2016; 22(5):319-26.
63. European Society of Clinical Microbiology and Infectious Disease. Extended-spectrum β-lactamase-producing Enterobacteriaceae: Detection of Resistance Mechanisms and Spesific Resistances of Clinical and/or Epidemiological Importance Guidelines. Swedia: EUCAST; 2017. p. 13-21.
64. Naas T, Cotellon G, Ergani A, Nordmann P. Real-time PCR for Detection of blaOXA-48 Genes from Stools. J Antimicrob Chemother. 2013; 68(1):101-4.
65. Khan E, Ejaz M, Zafar A, Jabeen K, Shakoor S, Inayat R, et al. Increased isolation of ESBL producing Klebsiella pneumonia with emergence of carbapenem resistent isolates in Pakistan : Report from a tertiary care hospital. J Pak Med Assoc. 2010; 60(3):186-90.
66. Sudigdo S. Dasar-dasar Metodologi Penelitian Klinis. Edisi Ke-4. Sagung Seto; 2011. hal. 362-3.
67. Richelsen R, Smit J, Anru PL, Schonheyder H, Nielsen H. Risk factors of community-onset extended-spectrum b-lactamase Escherichia coli and Klebsiella pneumoniae bacteraemia: an 11-year population-based caseecontrolecontrol study in Denmark. Clin Microbiol Infect. 2020; 74(20):1-7.
68. Lee Y, Kim YA, Kim D, Shin JH, Uh Y, Shin KS, et al. Risk factors of community-onset extended-spectrum β-lactamaseproducing Klebsiella pneumoniae bacteremia in South Korea using National Health Insurance claims data. Int J Antimicrob Agents. 2019; 54(6):723-7.
69. Salehi M, Jafari S, Ghafouri L, Ardakani HM, Abdollahi A, Beigmohammad MT, et al. Ventilator-associated Pneumonia: Multidrug Resistant Acinetobacter vs. Extended Spectrum Beta Lactamase-producing Klebsiella. J Infect Dev Ctries. 2020; 14(6):660-3.
70. Al-Garni SM, Ghonaim MM, Ahmed MMM, Al-Ghamdi AS, Ganai FA. Risk factors and molecular features of extended-spectrum beta-lactamase producing bacteria at southwest of Saudi Arabia. Saudi Med J. 2018; 39(12):1186-94.
71. Liu Y, Liu Y, Dai Y, Liu A, Li Y, Xu J, et al. Klebsiella pneumoniae pneumonia in patients with rheumatic autoimmune diseases: clinical characteristics, antimicrobial resistance and factors associated with extended-spectrum βlactamase production. BMC Infect Dis. 2021; 21(366):1-10.

72. Sharif MR, Soltani B, Moravveji A, Erami M, Soltani N. Prevalence and Risk Factors associated with Extended Spectrum Beta Lactamase Producing Escherichia coli and Klebsiella pneumoniae Isolates in Hospitalized Patients in Kashan (Iran). Electronic Physician. 2016; 8(3):2081-7.
73. Aaftab GP, Patil AB, Medegar S. Multivariate analysis of risk factors for ESBL and AmpC producing Escherichia coli and Klebsiella pneumoniae at a Tertiary Care Hospital in Karnataka: A case control study. IJMR. 2018;5(1):1-6.
74. Kim YA, Park YS, Kim B, Seo HY, Lee K. Prevalence and Risk Factors for Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae Colonization in Intensive Care Units. Ann Lab Med. 2020; 40(2):164-8.
75. Worotikan NI, Hasmono D, Kasih E, Ramdani D. Studi Penggunaan Sefalosporin Generasi Ketiga pada Pasien Pneumonia di Instalasi Rawat Inap Rumah Sakit Umum Haji Surabaya. J Pharm Sci & Pract. 2019; 6(2):66-73.
76. Liu J, Du SX, Zhang JN, Liu SH, Zhou YY, Wang XR. Spreading of extended-spectrum b-lactamase-producing Escherichia coli ST131 and Klebsiella pneumoniae ST11 in patients with pneumonia: a molecular epidemiological study. CMJ. 2016; 132(16):1894-1902. 76
77. Falcone M, Venditti M, Shindo Y, Kollef MH. Health Care Associated Pneumonia: diagnostic criteria and distinction from Community Acquired Pneumonia. Int J Infect Dis. 2011; 15(8):e545-50.
78. Piperaki ET, Syrogiannopoulos GA, Tzouvelekis LS, Daikos GL. Klebsiella pneumoniae: Virulence, Biofilm and Antimicrobial Resistance. PIDJ. 2017; 36(10):1002-5.
79. Deng J, Li YT, Shen Xu, Yu YW, Lin HL, Zhao QF, et al. Risk factors and molecular epidemiology of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in Xiamen, China. JGAR. 2017; 11:23-27. 79
80. Houard M, Rouze A, Ledoux G, Six S, Jaillette E, Poissy J, et al. Relationship between digestive tract colonization and subsequent ventilatorassociated pneumonia related to ESBLproducing Enterobacteriaceae. Plos One. 2018; 13(8):1-11. 80